Search News Archives
Special Offers and Promotions
Conferences | Events
FUJIFILM Irvine Scientific Opens New Armstrong R&D Cell Culture Center of Excellence
Construction completed for expanded facility within California headquarters
FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, has announced the completion of its Armstrong Cell Culture Center of Excellence. More than doubling the R&D facility’s footprint, the new state-of-the-art center enables the Company to expand its capabilities in cutting-edge discovery research, bioproduction, cell and gene therapy, Assisted Reproductive Technologies (ART) and cytogenetics.
Construction of the site, based at FUJIFILM Irvine Scientific’s headquarters in California, began in October 2021 and has recently been opened to its growing Life Sciences and Medical Media divisions. Having experienced significant growth in recent years, the Company continues to invest in new facilities globally, including opening new sites in Europe and Asia within the past year1,2. The new Armstrong Center will support many of its new programs and initiatives, including Manufacturing Sciences and Technologies (MSAT), Single-Use technology development, and automation platforms for media development. Alongside this, the expanded facility will offer dedicated workspace for cutting-edge research into analytical chemistry, virology, ART and additional cell culture and molecular based assay development, providing additional employment opportunities and projecting a doubling of growth in R&D headcount by the end of 2022.
Bob Newman, Chief Scientific Officer, FUJIFILM Irvine Scientific, commented: “Continuing our 50 years’ of success and experience in the cell biology and cell culture solutions industry, we are driving forward with expansion plans to support ongoing innovation and growth across our diverse offerings of specialty media, technologies, and custom media services.” He added: “The global demand for access to these high quality and cost-effective therapies and services is increasing faster than ever before. Through this new Californian site, as well as the recent opening of the Collaboration and Innovation Center in Suzhou New District, China, FUJIFILM Irvine Scientific is poised to provide enhanced technical collaboration opportunities between R&D experts worldwide, supporting development of personalized solutions and partnership opportunities.”
FUJIFILM Irvine Scientific, Inc., is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivaled service and quality to scientists working in biopharmaceuticals, cell therapy, and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA, and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 50 years, FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services. FUJIFILM Irvine Scientific, Inc. is a subsidiary of FUJIFILM Holdings America Corporation reporting to FUJIFILM Holdings Corporation.
FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship